Patents Represented by Attorney, Agent or Law Firm Jan P. Brunelle
  • Patent number: 6781028
    Abstract: Drosophila melanogaster and C. elegans that have been genetically modified to express or mis-express proteins involved in the sterol regulatory element binding protein (SREBP) pathway are described. These genetically modified animal models have identifiable phenotypes that make them useful in assays for studying lipid metabolism, other genes implicated in lipid metabolism, and compounds capable of modulating lipid metabolism pathways. Methods for studying lipid metabolism in living nematodes using fluorescently-labelled fatty acid conjugates, such BODITY™ fatty acid conjugates, are also described. Novel SREBP pathway nucleic acid and protein sequences are also described.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: August 24, 2004
    Assignee: Exelixis, Inc.
    Inventors: Michael R. Costa, Stephen K. Doberstein, Sarah L. Elson, Kimberly Carr Ferguson, Sheila Akiko Homburger
  • Patent number: 6762291
    Abstract: A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: July 13, 2004
    Assignee: Exelixis, Inc.
    Inventors: Andrew Roy Buchman, Darren Mark Platt, Michael Martin Ollman, Lynn Marie Young, Madelyn Robin Demsky, Kevin Patrick Keegan, Lori Friedman, Casey Kopczynski, Jeffrey S. Larson, Stephanie A. Robertson
  • Patent number: 6642438
    Abstract: The present invention is directed to a melon actin promoter capable of providing expression of heterologous genes, and nucleic acid constructs, vectors, transformation methods, transgenic plant cells, and transgenic plants comprising said promoter.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: November 4, 2003
    Assignee: Exelixis Plant Sciences, Inc.
    Inventors: Stephanie K. Clendennen, Jill A. Kellogg, Chau B. Phan, Helena V. Mathews, Nancy M. Webb
  • Patent number: 6599717
    Abstract: Vascular Endothelial Growth Factor Receptor (dmVEGFR) nucleic acids and proteins that have been isolated from Drosophila melanogaster are described. The dmVEGFR nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in dmVEGPR expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential therapeutics that interact with dmVEGFR protein. They can also be used in methods for studying dmVEGFR activity and identifying other genes that modulate the function of, or interact with, the dmVEGFR gene.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: July 29, 2003
    Assignee: Exelixis, Inc.
    Inventors: Allen James Ebens, Jr., R. Glenn Hammonds, Jonathan C. Heller, Greg Weddell, John W. Winslow
  • Patent number: 6579701
    Abstract: Novel nucleic acids that are homologs of genes implicated in cancer are described that have been isolated from Drosophila melanogaster. These novel nucleic acids can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in novel gene expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential pesticidal agents or therapeutics that interact with gene products implicated in cancer. They can also be used in methods for studying gene activity and identifying other genes that modulate the function of, or interact with, genes implicated in cancer.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: June 17, 2003
    Assignee: Exelixis, Inc.
    Inventors: Kevin Patrick Keegan, Thomas J. Stout
  • Patent number: 6563023
    Abstract: The present invention is directed to a novel plant phenotype, designated CURLY (CUR), a nucleic acid sequence expressed in plants demonstrating the CUR phenotype and the corresponding amino acid sequence. Also provided are plant cells and plants that exhibit modified CUR expression.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: May 13, 2003
    Assignee: Agrinomics, LLC
    Inventors: Alex Liu, Jill Van Winkle, Susan M. Bovee-Picciano, Stanley R. Bates, Helena V. Mathews, Ry Wagner
  • Patent number: 6534695
    Abstract: The present invention is directed to a novel plant phenotype, designated DWARF AND LATE FLOWERING 2 (DLF2), a nucleic acid sequence expressed in plants demonstrating the DLF2 phenotype and the corresponding amino acid sequence. Also provided are plant cells and plants that exhibit modified DLF2 expression.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: March 18, 2003
    Assignee: Agrinomics LLC
    Inventors: Alex Liu, Jill Van Winkle, Susan Bovee-Picciano, Helena Mathews
  • Patent number: 6515109
    Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: February 4, 2003
    Assignee: Exelixis, Inc.
    Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly
  • Patent number: 6511824
    Abstract: Tandem pore domain weak inward rectifying K+ (TWIK) channel nucleic acids and proteins that have been isolated from Drosophila melanogaster and Leptinotarsa are described. The TWIK channel nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms, such as insects, coelomates, and pseudocoelomates, or cultured cells, resulting in TWIK channel expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential pesticidal agents or therapeutics that interact with TWIK channel proteins. They can also be used in methods for studying TWIK channel activity and identifying other genes that modulate the function of, or interact with, the TWIK channel gene.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: January 28, 2003
    Assignee: Exelixis, Inc.
    Inventors: Andrew Roy Buchman, Christian Burks, Helen Louise Francis-Lang, Lucile A. Gillett, Jonathan Cagampang Heller, Casey Casimir Kopczynski, Jonathan Scott Margolis, Darren Mark Platt, Bindu Priya Reddy, Candace Swimmer, John W. Winslow, Yuling Luo
  • Patent number: 6509191
    Abstract: The present invention is directed to a novel plant phenotype, designated PAGODA (PGD), a nucleic acid sequence expressed in plants demonstrating the PGD phenotype and the corresponding amino acid sequence. Also provided are plant cells and plants that exhibit modified PGD expression.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: January 21, 2003
    Inventors: Alex Liu, Helena Mathews, Jill Van Winkle, Ry Wagner, Stanley R. Bates, Susan Bovee-Picciano
  • Patent number: 6465169
    Abstract: A method for cryoconservation of Zebrafish sperm, and Zebrafish sperm obtained by said method.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: October 15, 2002
    Assignee: Artemis Pharmaceuticals GmbH
    Inventors: Brigitte Walderich, Renate Nordin
  • Patent number: 5877273
    Abstract: The present invention relates to nucleotide sequences of Actinomycetales, in particular of mycobacteria, to oligonucleotides contained within said nucleotide sequences, to their uses as primers for the synthesis of Actinomycetales DNA and as probes for the detection of DNA and/or the transcription products of Actinomycetales, in particular of mycobacteria, to the products of expression of said sequences, to their uses and to antibodies directed towards the said products, to a method for detecting and identifying Actinomycetales and its uses, as well as to immunogenic compositions comprising the said expression products.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 2, 1999
    Assignee: Institut National de la Sante et de la Recherche Mediale-Inserm & Institute Pasteur
    Inventors: Allan Johnson Hance, Bernard Grandchamp-Desraux, Veronique Levy-Frebault, Brigitte Gicquel
  • Patent number: 5851761
    Abstract: The invention provides nucleotide probes, kits and methods for the detection and differentiation of Mycobacteria. The gene probes, kits and methods are useful for the diagnosis of tuberculosis and/or for epidemiological study tools for investigating the progress of infections caused by Mycobacteria.The gene probes as provided comprise part or all of nucleotide sequences provided in the soecification or an allele or a derivative of the nucleotide sequences.The gene probes can distinguish between M.tuberculosis, M.bovis and BCG as well as being able to distinguish between different strains of M.tuberculosis. The probes do not show significant hybridisation to nucleic acids from M.paratuberculosis, M.intracellulare, M.scrofulaceum, M.phlei, M.fortuitum, M.kansasii, M.avium, M.malnioense. M.flavescens, M.gordonae and M.chelonei.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: December 22, 1998
    Assignee: Cogent Limited
    Inventors: Ruth Anne McAdam, Jeremy Watson Dale, Zainul Fadziruddin Bin Zainuddin, David Catty
  • Patent number: 5830255
    Abstract: Concentrated phosphorus fertilizers are disclosed that comprise a buffered composition of an organic acid and salts thereof and a phosphorous-containing acid and salts thereof. The concentrated phosphorus fertilizers can be diluted with water of pH ranging from about 6.5 to about 8.5 at ratios of concentrate to water at about 1:40 to about 1:600 to result in a fertilizer having a pH in the range acceptable for foliar uptake of phosphorus.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: November 3, 1998
    Assignee: The Regents of the University of California
    Inventor: Carol J. Lovatt
  • Patent number: 5719054
    Abstract: The invention provides a recombinant virus vector for use as an immunotherapeutic or vaccine. The recombinant virus vector comprises at least one pair of nucleotide sequences heterologous to the virus and which have sufficient sequence homology that recombination between them might be expected. The pair of nucleotide sequences are arranged in the virus vector such that they are inverted with respect to each other. The virus vector is able to infect a mammalian host cell and express as polypeptide the heterologous nucleotide sequences in the host cell. For infection thought to be caused by HPV infection, the pair of nucleotide sequences encode part or all of human papillomavirus (HPV) wild-type proteins or mutant proteins immunologically cross-reactive therewith. For an immunotherapeutic or vaccine against cervical cancer, the recombinant virus vector encodes part or all of the HPV wild-type proteins HPV16E7 and HPV18E7 or mutant proteins immunologically cross-reactive therewith.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: February 17, 1998
    Assignee: Cantab Pharmaceuticals Research Limited
    Inventors: Michael E. Boursnell, Stephen C. Inglis, Alan J. Munro
  • Patent number: 5677440
    Abstract: Conjugates of the type Z--X--L are described wherein Z is a solid phase matrix, X is a single amino acid or a polyamide of two or more amino acid residues, and L is a linker that is capable of linking between the amino terminus of X and a 3'-phosphate of a nucleotide. Conjugates may also be synthesized by assembling a polyamide on a solid support matrix, adding a suitable linker molecule, followed by synthesis of an oligonucleotide thereon. Methods for detecting specific polynucleotides with oligonucleotide-polyamide conjugates are also described.
    Type: Grant
    Filed: February 9, 1996
    Date of Patent: October 14, 1997
    Assignee: Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Jim Haralambidis, Geoffrey William Tregear
  • Patent number: 5672805
    Abstract: The present invention provides non-human, transgenic animals for use as a model for the study of Alzheimer's Disease. The animals exhibit pathology associated with Alzheimer's Disease. The phenotype is conferred in the animals by the introduction of an amyloid-containing polypeptide fragment of amyloid precursor protein, through the introduction of the DNA into the germ and somatic cells of the animal by transgenic methods.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: September 30, 1997
    Assignee: The Regents of the University of California
    Inventor: Rachael L. Neve
  • Patent number: 5654258
    Abstract: A solid, water dispersible, storage-stable trifluralin formulation comprises trifluralin supported inside porous, finely divided carrier particles, optionally together with at least one compatible wetting agent and/or dispersant additive, wherein the trifluralin is in the orange polymorphic form and the particles of the formulation are size-stable.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: August 5, 1997
    Assignee: Daratech Pty. Ltd.
    Inventors: Darren James Park, Gottfried Lichti
  • Patent number: 5567597
    Abstract: The present invention provides compounds that function as hydrolytic enzyme inhibitors (inactivators) and substrates. These compounds are useful in assays to detect and measure levels of hydrolytic enzyme activity and are more particularly useful in treatment regimens for various disease states and conditions implicating the underlying specific hydrolytic enzyme. Examples of hydrolytic enzymes include, but are not limited to, phospholipases, lipases, esterases, proteases, etc.
    Type: Grant
    Filed: February 14, 1995
    Date of Patent: October 22, 1996
    Assignee: The Regents of the University of California
    Inventors: Edward A. Dennis, William N. Washburn
  • Patent number: 5525465
    Abstract: Oligonucleotide-polyamide conjugates of the formula X--L--Y, where X is a polyamide, Y is an oligonucleotide, and L is a linker which forms a covalent bond with the amino-terminus of the polyamide X and the 3' phosphate group of the oligonucleotide Y. Conjugates may be synthesized by assembling a polyamide on a solid support matrix, adding a suitable linker molecule, followed by synthesis of the oligonucleotide. Methods for detecting specific polynucleotides with oligonucleotide-polyamide conjugates are also described.
    Type: Grant
    Filed: January 3, 1995
    Date of Patent: June 11, 1996
    Assignee: Howard Florey Institute of Experimental Physiology and Medicine
    Inventors: Jim Haralambidis, Geoffrey W. Tregear